NRG Therapeutics

 

  Follow

Location: United Kingdom

Founded in 2018

Privately Held


Develops disease-modifying therapeutics utilizing mitochondrial biology breakthroughs to slow or halt neurodegenerative disorders progression, including Parkinson's and ALS.
"NRG Therapeutics is applying science in the field of mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and ALS (also known as motor neurone disease or MND). Its pre-clinical pipeline includes small molecule assets which inhibit the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action."
Description Source: VentureRadar Research / Company Website

Updates


UK Life Sciences Future50 (2023)
Award
02 Dec 2023
One of the "Future50" companies
Source: pwc.co.uk
UK Life Sciences Future50 (2023)
Research Report
02 Dec 2023
One of the "Future50" companies
Source: pwc.co.uk
Venture-funding News
Equity Funding
09 Nov 2022
NRG Therapeutics Raises £16M in Series A Funding
Source: finsmes.com
Innovate UK Award
Grant
01 May 2022
Funding Award (Collaborative R&D): Development of Mitochondrial Permeability Transition Pore Inhibitors for the Treatment of Neurodegenerative Diseases / Lead Participant: Yes
Source: gtr.ukri.org

Funding Signals


VENTURE FUNDED

Venture-funding News

GOVERNMENT GRANT

Export Similar Companies

Similar Companies


Company Country Status Description
MitobridgeUSAPrivately Held
Mitobridge is discovering and developing novel therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction...
MitoRx TherapeuticsUnited KingdomPrivately Held
MitoRx aims to become a global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction. The company is a preclinical research...
Mitoimmune TherapeuticsSouth KoreaPrivately Held
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as...
Celosia TherapeuticsAustraliaPrivately Held
Celosia Therapeutics is a biotechnology company developing advanced gene therapies to treat neurodegenerative diseases such as ALS, MND, epilepsy, and dementia. Utilizing a...
Neuroene Therapeutics LLCUSAPrivately Held
Neuroene Therapeutics is pioneering treatments for neurological diseases by addressing mitochondrial dysfunction, a common trait in conditions like epilepsy, Parkinson’s, and rare...
MitoChem TherapeuticsUSAPrivately Held
Founded at the Medical University of South Carolina, MitoChem Therapeutics was started by two scientists who saw an opportunity to focus on developing treatments to address the...
Show all
VentureRadar Score

Is this your company?

Claim this profile and
update details for free
Sub-Scores
Social Proof
980
Website Traffic
68
Auto Analyst Score
500
Popularity on VentureRadar
986
Website Popularity
Low Traffic Sites
Low
High Traffic Sites
High
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Open PageRank: 9,315,410 | nrgtherapeutics.com
Auto Analyst Score
50
Auto Analyst Score: 50 | nrgtherapeutics.com
VentureRadar Popularity
High
VentureRadar Popularity: High
The popularity score combines profile views, clicks and the number of times the company appears in search results.

Free Sign-up for VentureRadar access

or






By continuing, you agree to VentureRadar's Terms of Service, Privacy Policy and Cookie Policy.

To continue, please confirm you are not a robot